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Summary
Objectives: To determine whether the measured change in score of a validated
clinical severity scale reflected physician assessed improvement in individuals who
had received corticosteroid therapy for leprosy associated nerve damage.
Design: Patients with nerve function impairment who participated in a randomised
controlled trial of corticosteroids were classified into two groups using a
retrospectively determined physician assessment of improvement. One group
consisted of patients who had recovered or improved the other of patients who were
unchanged or had deteriorated. The change in the clinical severity scale scores of
these two groups was compared.
Results: The change in the clinical severity scale scores of the 34 eligible
individuals in the two groups were significantly different (P ¼ 0·003). Individuals in
the group who recovered or improved had a greater change in severity score than
those whose nerve function was unchanged or deteriorated.
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Conclusion: The scale for measuring the severity of leprosy Type 1 reactions
(T1Rs) and/or nerve function impairment reflects the clinical improvement of
individuals with leprosy associated nerve damage.
Introduction
Clinical trials with appropriate outcome measures are needed to determine the most effective
treatment regimens for Type 1 reactions (T1Rs) and/or nerve function impairment (NFI).1 It
has proved difficult to compare the small number of studies because of the different outcome
measures used.2 There are also difficulties in comparing the severity of T1Rs between
different cohorts and even between different arms of clinical trials.2,3
A tool that enables clinicians to accurately assess the severity of leprosy T1Rs would be
useful in defining outcomes for clinical trials. It is important that such a scale would reflect
clinical outcomes following therapy and as a measure of efficacy in clinical trials. An
appropriate measure would facilitate confirmation of the even distribution of patients with
similar disease severity between the arms of clinical trials, could be used in treatment
guidelines to define the need for therapy and may be useful in determining prognosis.
We wished to compare the change in severity score with a retrospective physician
assessment of neurological outcome in leprosy patients treated with corticosteroids for T1R
and/or NFI.
A scale to measure the severity of leprosy T1Rs and leprosy associated NFI was
developed and validated in Bangladesh and Brazil.4 This is a reliable 21 item scale for
measuring the severity of T1Rs and NFI in leprosy patients (see Appendix 1). Neurological
items are well represented and reflect the importance of NFI. The scale requires the examiner
to be proficient in recognising the cutaneous signs of T1R, the assessment of motor function
using voluntary muscle testing (VMT) and the use of Semmes-Weinstein monofilaments
(SWM) to assess sensory function. The possible range of scores is 0–63, the lower the score
the less severe the reaction (or NFI). The maximum score possible for sensory NFI and motor
NFI are 24 and 30 respectively. How the scale reflects change following treatment of
individuals with NFI with corticosteroids was not assessed in the validation studies. The scale
was used concurrently in a Nepali cohort of leprosy patients with T1Rs and NFI in a clinical
trial of corticosteroid treatment.5 Here we further analyse the data from that study and
compare a physician determined outcome (in individuals with nerve function impairment)
with change in severity score. The rationale of the study is to compare a subjective physician
determined assessment of improvement with a more objective, repeatable and quantifiable
measure. This analysis indicates the utility of the score derived from the clinical severity scale
in a clinical trial setting.
Methods
The participants were individuals with T1Rs and/or new NFI (of less than 6 months duration)
who were recruited from the leprosy clinic at Anandaban Hospital in Nepal. They were
enrolled between December 2005 and December 2007 in a double blind placebo controlled
trial. All participants gave written informed consent. They were randomised to receive
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intravenous methylprednisolone (1 g) followed by a reducing course of oral prednisolone or
intravenous placebo and a reducing course of prednisolone alone for a total of 16 weeks. They
were followed for a total of 337 days from enrolment. Patients with deterioration in nerve
function or skin signs were treated with further prednisolone.
The methods and participants have been described previously.5 Briefly, sensory testing
(ST) was performed using two SWM (Sorri-Bauru, Bauru, Sa˜o Paulo, Brazil) at designated
test sites on the hands and feet. Ulnar and median nerve function was tested with 2 g and 10 g
monofilaments. The posterior tibial nerve function was tested with the 10 g and 300 g
monofilaments. Trigeminal nerve sensation was tested using cotton wool. VMT was assessed
using the modified Medical Research Council (MRC) grading of power.6 ST and VMT
assessments were carried out by trained physio-technicians and, if necessary, repeated by the
study physicians. NFI was defined as: an inability to feel the 2 g monofilament on the hand or
the 10 g monofilament on the foot, or reduced power (, MRC grade 5) on VMT. The clinical
severity score was calculated for each participant at the time of enrolment into the study and
at all subsequent assessments.
A retrospective physician assessment of neurological outcome was done at the end of the
trial in those individuals who had NFI of less than 6 months duration at enrolment and who
had completed the study intervention. The assessment was done by comparing participants’
baseline sensory and motor examinations with their last recorded assessment (performed at
day 337 of the trial or at the last assessment before being lost to follow up). The designated
outcomes were: recovered, improved, unchanged or deteriorated. Recovery was defined as
the ability to feel the 2 g monofilament at all test sites on the hands, the 10 g at all sites on the
feet and power of grade 5 in all tested muscles. However, inclusion of an individual in the
other categories was left to the discretion of the physician. The clinical severity score was not
used to determine the physician assessment. Nerves with longstanding NFI of greater than 6
months at enrolment were recorded and included in the assessment. NFI of this duration
would not be expected to improve with corticosteroid therapy.7 The difference between the
neurological components of the clinical severity score at baseline and their last recorded
assessment were calculated. A negative value indicates deterioration in function.
The study was approved by the Nepal Health Research Council and the Ethics Committee
of the London School of Hygiene and Tropical Medicine (Number 4022). The trial was
registered with Current Controlled Trials Ltd (www.controlled-trials.com) in accordance with
the policy of the International Committee of Medical Journal Editors8 and was assigned the
unique identifier ISRCTN31894035.
The data were analysed using the Statistical Package for the Social Sciences (SPSS
version 16. SPSS Inc., Chicago, Illinois) and GraphPad Prism (version 4.02 for Windows,
GraphPad Software, San Diego, California). Comparison between groups was made using
the Mann Whitney U test. The threshold for accepting statistical significance was ,0·05.
Results
Forty-two individuals participated in the randomised controlled trial. Six individuals did not
have any evidence of NFI at enrolment and two others did not complete the study
intervention. Thirty-four individuals had NFI at enrolment and completed the 16 week course
of corticosteroid therapy and were included in the analysis for this study (see Table 1).
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Twenty-eight of these had completed the full period of follow up. The remaining six had
completed the 16 week study intervention and had been followed up for between 119 and 299
days in total. Twenty individuals (58·8%) required additional prednisolone.
The baseline assessment severity scores of individuals who received intravenous
methylprednisolone and oral prednisolone and those who received oral prednisolone alone
were not significantly different. The severity scores at enrolment between those classified as
recovered or improved and those classified as unchanged or worse were not significantly
different. There were no significant differences in the baseline scores of individuals who had
their final assessment at day 337 and those who had their final assessment between days 119
and 299) or in the baseline scores of those who received additional prednisolone and those
who did not.
Eleven (out of 34) individuals had some NFI present for more than 6 months at the time of
enrolment. These 11 patients had 36 nerves (21 sensory and 15 motor) which were affected by
longstanding (. 6 months) NFI. At the last recorded assessment the changes in longstanding
NFI were as follows: only one sensory nerve had recovered, three posterior tibial nerves had
improved by a median monofilament score of 0·5. Thirteen were unchanged and four sensory
nerves had deteriorated by a median score of 0·75. Four motor nerves recovered but all had
the mildest possible deficit at baseline; a VMT score of one (equivalent to MRC grade 4
power). Ten motor nerves had unchanged function, including eight that had a maximal VMT
score of three. The function in one motor nerve deteriorated from a scale score of two to three.
The physician assessment of neurological outcome demonstrated that seven (20·6%)
individuals who had nerve damage at baseline of less than 6 months duration and had
completed a 16 week course of corticosteroid therapy recovered. Only one of these seven
individuals had NFI of greater than 6 months duration. This individual had mild impairment
(MRC Grade 4) of the motor function of the right ulnar nerve which recovered. Seventeen
individuals of 34 (50%) had an improvement in their nerve function. Five of these individuals
had NFI of greater than 6 months duration but none had more than two nerves affected in this
way. However, nine participants (26·5%) had nerve function that was unchanged and one
individual’s nerve function had deteriorated. Of the nine participants who were unchanged,
five had longstanding NFI with a median number of six nerves affected in this way (Range
2–8). Table 2 shows the number of individuals in each category and the range and median
change in severity scores for each category. There were no statistical differences between the
groups with respect to the proportion of individuals with old nerve damage (. 6 months).
Individuals were grouped according to their status with respect to the physician
assessment of neurological outcome as shown in Figure 1.
Table 2. Post-hoc physician assessment of neurological outcome and change in clinical severity score (neurological
items only)
Number
(n ¼ 34)
Individuals
with NFI
. 6 months
Median number
of nerves with
NFI . 6 months
Range of
change in
severity
score
Median
change in
severity
score
Recovered 7 1 1 1–10 3
Improved 17 5 2 0–21·5 4
Unchanged 9 5 6 0–9·5 0·5
Deteriorated 1 0 – – 22·5
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The median change in nerve score between the baseline and the final recorded
assessments were significantly different (P ¼ 0·003).The number of nerves with old NFI in
the “Unchanged/Deteriorated” group was significantly greater than that in the “Recovered/
Improved” group (P ¼ 0·048).
Discussion
We compared the median change in the clinical severity scores between the
recovered/improved and no change/deteriorated groups identified by physician assessment
and found a statistically significant difference with greater reduction in score in the
improved/recovered group. The significant difference in the number of nerves affected by
longstanding NFI between the two groups also supports the contention that the scale is able to
discriminate outcomes as it would be expected that those with a greater number of affected
nerves would have a poorer outcome. These findings should be interpreted with caution
because of the small numbers in the cohort; also the scale has not been formally validated in
Nepali patients and the criterion for improvement (post hoc physician assessment)
is somewhat subjective. A more robust study could be designed using methodologies to
prospectively assess clinical improvement and use patient centred outcomes such as
minimally important difference (MID). MID is a patient centred outcome measure that
quantifies the smallest change in a score that is worthwhile or important.9 The scale needs to
be assessed using MID which will allow any change in severity score to be interpreted in
clinically meaningful ways. This should be performed in a population in which the scale has
*
Recovered or improved
(n=24)
AN27
AN26
AN11
25·0
20·0
15·0
10·0
5·0
–5·0
0·0
Deteriorated or unchanged
(n=10)
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er
ve
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on
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en
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oto
r)
Figure 1. Change in nerve score and clinical outcome in those completing corticosteroid course (n ¼ 34). (Circles
denote individuals 1·5 times the interquartile range (IQR) outside the box and asterisks denote individuals 3 times the
IQR outside the box).
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been validated. Knowing the magnitude of the change in score required to achieve a MID
would facilitate power calculations for clinical trials.
The retrospective physician assessment, although not a stringent outcome, reveals the
high rates of persistent neurological impairment even after individuals have completed at
least one prolonged course of corticosteroid therapy. In this study 70·6% (24/34) of those
treated with at least 16 weeks of corticosteroid improved or recovered. This is consistent with
data from Bangladesh where 67% of nerves improved after a 16 week course of
prednisolone.10 The study conducted in Nepal by Marlowe et al. of prednisolone and a
combination of azathioprine and prednisolone reported improvement in sensory function in
57·1% of individuals with sensory impairment present for less than 6 months.11 The figure
was identical for those with motor impairment before the start of treatment.
A significant finding of the randomised controlled study of intravenous methylpredni-
solone was that almost 50% of those enrolled required a further course of prednisolone in
addition to the study interventions.5 The proportion receiving additional prednisolone was
slightly higher (58·8%) in the sub-group of individuals who had NFI at enrolment.
The significant difference in the change in nerve score between individuals who were
better or improved and those who were unchanged or worse in the Nepali cohort, although a
preliminary finding, suggests that the scale reflects clinically relevant change. Further studies
of the clinical severity scale are warranted to determine its utility in future clinical studies.
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